

# Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)

NCT07317934

---

Status	RECRUITING
Phase	Phase 3
Sponsor	Innostellar Biotherapeutics Co.,Ltd
Enrollment	332 participants

## Key Eligibility Criteria

---

### Inclusion (7)

- Willing and able to provide written, signed informed consent for this study;
- Age e50 and d80 years old;
- active CNV secondary to nAMD in the study eye confirmed by FFA or OCT;
- The BCVA between 24 and 78 letters (inclusive) in the study eye at Screening;
- Demonstrated clinical response to aflibercept treatments in the study eye confirmed by the Reading Center;
- ... and 2 more (see full listing online)

### Exclusion (10)

- Any condition in the investigator's opinion that could limit VA improvement in the study eye.
- CNV or macular edema in the study eye secondary to any causes other than AMD
- Subfoveal fibrosis or atrophy in the study eye, as determined by CRC;
- History of retinal detachment in the study eye at any time;
- History of idiopathic or autoimmune uveitis in either eye;
- ... and 5 more (see full listing online)

## Locations (31 total)

---

The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China  
Beijing Hospital, Beijing, Beijing Municipality, China  
Peking Union Medical College Hospital, Beijing, Beijing Municipality, China  
... and 28 more locations